Prognostic impacts of Lipoxin A4 in patients with acute myocardial infarction: A prospective cohort study

Abstract

Lipoxin A4 (LXA4) is one of the specialized pro-resolving lipid mediators proved to suppress the progression of atherosclerosis in vivo, but its clinical impacts in atherosclerotic patients is unclear. In this study, we assessed the prognostic impacts of LXA4 in patients with acute myocardial infarction (AMI). A total of 1569 consecutive AMI patients were prospectively recruited from March 2017 to January 2020. Plasma samples of AMI patients were collected, and LXA4 levels were determined using enzyme-linked immunosorbent assay. The primary outcome was major adverse cardiovascular event (MACE), a composite of all-cause death, recurrent MI, ischemic stroke, or ischemia-driven revascularization. Cox regression was used to assess associations between LXA4 and clinical outcomes. Overall, the median level of LXA4 was 5.637 (3.047-9.014) ng/mL for AMI patients. During a median follow-up of 786 (726-1108) days, high LXA4 (≥ 5.637ng/mL) was associated with lower risk of MACE (hazard ratio [HR]: 0.73, 95% confidence interval [CI]: 0.60-0.89, P=0.002), which was sustained in propensity score matching (HR: 0.73, 95% CI: 0.60-0.90, P=0.004) and inverse probability weighting analysis (HR: 0.74, 95% CI: 0.61-0.90, P=0.002). Combined with pro-inflammatory biomarker, patients with high levels of LXA4 (≥ 5.637ng/mL) but low levels of high-sensitivity C-reactive protein (< 5.7mg/L) acquired the lowest risk of MACE (HR: 0.68, 95% CI: 0.51-0.92, P=0.012). In sum, high levels of LXA4 were associated with lower risk of recurrent ischemic events for AMI patients, which could serve as new therapeutic target to tackle cardiovascular inflammation.